A look at Amgen
Headquartered in Thousand Oaks, California, Amgen (AMGN) is a biotechnology company. It discovers, develops, and delivers drugs for therapeutic areas including cardiovascular, neuroscience, and oncology.
The above chart compares the changes in analysts’ recommendations for Amgen over the last 12 months.
Amgen stock rose 8.4% in May. The stock has risen 5.6% year-to-date as of June 4.
Wall Street analysts estimate that Amgen stock has the potential to return 6% over the next 12 months. They have given it a 12-month target price of $195.35 per share compared to $183.57 per share on June 1.
There are 23 analysts tracking Amgen stock. Five of them have recommended a “strong buy,” six have recommended a “buy,” and 15 have recommended a “hold.” None of them have recommended a “sell.” The consensus rating for Amgen is 2.4, which represents a “strong buy” for value investors.
Analysts’ revenue estimates
Amgen’s revenues are mainly driven by growth in revenues at constant exchange rates. Its revenues are negatively impacted by foreign exchange.
Wall Street analysts estimate revenues of $5.7 billion in the second quarter, which would be a 1.2% decline year-over-year. They expect EPS of $3.54.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!